POOLBEG PHARMA PLC

Regulatory News Service • Nov 20, 2025

National Storage Mechanism | Additional information

RNS Number : 2434I

Poolbeg Pharma PLC

20 November 2025

Poolbeg Pharma plc

POLB 001 European Patent granted

Further strengthens Poolbeg's global intellectual property portfolio

20 November 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg's European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza.

POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention and treatment of cancer immunotherapy-induced Cytokine Release Syndrome ("CRS"), a potential market opportunity of over US$10 billion, and the treatment of severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally.

Poolbeg is actively building a comprehensive, worldwide IP portfolio, with patents covering use of p38 MAPK inhibitors in patients with severe influenza and for the prevention and treatment of cancer immunotherapy-induced CRS. This patent grant further strengthens the Company's robust intellectual property portfolio, enhancing POLB 001's value and appeal to potential partners.

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: "This patent grant from the European Patent Office highlights the strong progress we continue to make in developing and strengthening our IP portfolio for POLB 001 across multiple disease indications. This further enhances the value and attractiveness of POLB 001 for potential partners."

Enquiries

Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO	+44 (0) 207 183 1499 [email protected]
Cavendish Capital Markets Ltd (NOMAD & Joint Broker) Geoff Nash, Trisyia Jamaludin (Corporate Finance) Nigel Birks (Life Science Specialist Sales) Harriet Ward (ECM)	+44 (0) 207 220 0500
Shore Capital Stockbrokers Ltd (Joint Broker) David Coaten, Harry Davies-Ball (Corporate Advisory) Malachy McEntyre (Corporate Broking)	+44 (0) 207 408 4090
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist	+353 (0) 1 679 6363
Optimum Strategic Communications Nick Bastin, Vici Rabbetts, Elena Bates	+44 (0) 208 078 4357 [email protected]

About Poolbeg Pharma plc 

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. 

Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBLBFTMTABBIA